Advanced drug delivery system with nanomaterials for personalised medicine to treat breast cancer
Autor: | Nairuti Patel, Chinedu S. Ekweremadu, Hyun Jee Han |
---|---|
Rok vydání: | 2019 |
Předmět: |
Drug
medicine.medical_specialty business.industry media_common.quotation_subject Pharmaceutical Science 02 engineering and technology 021001 nanoscience & nanotechnology medicine.disease 030226 pharmacology & pharmacy 03 medical and health sciences 0302 clinical medicine Breast cancer Drug delivery medicine Nanomedicine 0210 nano-technology Intensive care medicine business Drug toxicity Reimbursement media_common |
Zdroj: | Journal of Drug Delivery Science and Technology. 52:1051-1060 |
ISSN: | 1773-2247 |
DOI: | 10.1016/j.jddst.2019.05.024 |
Popis: | Nanomaterials implemented for external targeting of drugs to solid tumours are a promising tool which can achieve a more stable and long-acting formulation. Nanomedicine has become a popular field due to its properties which include its small size, reduced drug toxicity, controlled release of the drug and ease of biological distribution. However, despite the potential of personalized nanotherapeutics in breast cancer management, no product has been registered in the market in this regard. Thus, there is an urgent need for these life-saving commodities. It is this novel drug delivery system which has opened up the potential for the development of personalised medicine across several stratified groups of breast cancer. Through the use of nanomedicine, this paper suggests ways in which breast cancer can be treated based on personalised strategies. The paper also incorporates possible ideas of its application in a clinical setting, along with the emerging concept of nanomaterial induced endothelial leakiness, which is posing a doubt in the success of developing nanomedicine therapies for breast cancer. In spite of the risks involved in commercializing personalised nanoformulations for breast cancer management, big pharma can create value for shareholders by delivering personalised nanotherapeutics to breast cancer patients with an innovative business model and a supporting reimbursement scheme. |
Databáze: | OpenAIRE |
Externí odkaz: |